Currax Pharmaceuticals

New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE/MYSIMBA Amidst GLP-1 Supply Issues

23 July 2024 -- Tennessee, US -- Currax Pharmaceuticals LLC today announced the approval of additional manufacturing site for CONTRAVE/MYSIMBA in the European Union (EU) and European Union Economic Areas (EEA). The new site doubles the current production capacity of CONTRAVE/MYSIMBA and ensures continuity of supply, and the site has capacity to increase production when...
155 Franklin Road, Suite 450 Brentwood, TN 37027

800-793-2145